Gilead Sciences Inc (GILD)

Keymed Biosciences achieved a major windfall by spinning off its immunotherapy drug into a separate company (Ouro Medicines) that was subsequently acquired by Gilead Sciences for up to $2.175 billion. Keymed stands to receive approximately $320 million in total proceeds while retaining royalty rights. The transaction marks the first complete NewCo cycle exit by a Chinese drugmaker and demonstrates the effectiveness of this globalization strategy for Chinese biotech companies.

Benzinga•Bamboo Works

Apr 2

The article highlights two dividend-growth stocks that have pulled back due to Middle East tensions despite having no exposure to the conflict. Waste Management (WM) is investing $1.4 billion in AI-powered automation to boost efficiency and free cash flow growth, while Gilead Sciences (GILD) is leveraging AI to accelerate drug development timelines. Both stocks offer attractive entry points with accelerating dividend growth and strong underlying fundamentals.

Investing.com•Brett Owens

Mar 31

Galapagos NV has entered into a binding framework agreement with Gilead Sciences to collaborate on developing gamgertamig, a clinical-stage BCMA×CD3 T cell engager for autoimmune diseases. Under the deal, Galapagos will receive 50% of Gilead's $1.675 billion upfront payment for acquiring Ouro Medicines plus 50% of contingent milestone payments. Galapagos will retain $500 million in cash for independent strategic initiatives and is eligible for up to $100 million in additional milestone payments, with tiered royalties of 20-23% on net sales.

Benzinga•

Mar 31

The global bile duct cancer market is projected to expand from $2.59 billion in 2025 to $3.89 billion by 2030, growing at an 8.4% CAGR. Growth is driven by advancements in early diagnostics, increased adoption of immunotherapy and targeted therapies, AI-assisted diagnostics, and rising prevalence of liver diseases. Major pharmaceutical companies are introducing innovative treatments and forming strategic partnerships to enhance patient outcomes.

GlobeNewswire Inc.•Researchandmarkets.Com

Mar 30

SK pharmteco announced it will host a one-day scientific symposium on April 8th in Cambridge, Massachusetts focused on continuous manufacturing, advanced processing, and scalable technologies in pharmaceutical production. The event will feature keynote speakers and expert panels from leading organizations including Gilead, Antheia, Eli Lilly, and Amgen to discuss the future of pharmaceutical manufacturing.

GlobeNewswire Inc.•Sk Pharmteco

Mar 26

Gilead Sciences agreed to acquire Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments to strengthen its inflammation and autoimmune disease pipeline. The clinical-stage drug OM336, a bispecific T cell engager, will be co-developed with Galapagos NV, which will fund 50% of upfront costs and development expenses through registrational studies. Gilead retains global commercialization rights and will pay Galapagos 20-23% royalties on net sales.

Benzinga•Vandana Singh

Mar 24

Galapagos and Gilead are in advanced partnership discussions following Gilead's acquisition of Ouro Medicines for $1.675 billion upfront plus up to $500 million in milestone payments. Under the proposed collaboration, Galapagos would pay 50% of acquisition costs, absorb Ouro's operating assets, and lead development through registrational studies, while Gilead retains commercialization rights and pays 20-23% royalties. The partnership would free up $500 million of Galapagos' cash for independent strategic initiatives.

GlobeNewswire Inc.•

Mar 23

Galapagos and Gilead are in advanced discussions for a strategic partnership following Gilead's acquisition of Ouro Medicines. Under the proposed collaboration, Galapagos would co-develop OM336 (gamgertamig), a BCMA-targeted T-cell engager for autoimmune diseases, with improved financial terms including 50% cost-sharing for registration studies and 20-23% royalties on net sales. The deal would also free up €500 million of Galapagos' capital for strategic flexibility.

GlobeNewswire Inc.•

Mar 23

Cormorant Asset Management sold its entire $63.63 million stake in Arcellx (775,000 shares) in Q4, completely exiting a position that represented 4.4% of its AUM. The exit proved poorly timed, as Arcellx shares surged following Gilead Sciences' takeover announcement valuing the company at $7.8 billion with an offer of $115 per share plus potential milestone payments. Arcellx shares are up 80% this year, significantly outperforming the S&P 500.

The Motley Fool•Jonathan Ponciano

Mar 16

The article highlights three companies with strong cash flow generation as reliable investments during market uncertainty in 2026: Gilead Sciences with a 6% free cash flow yield and commitment to returning 63% of annual free cash flow to shareholders; AbbVie with over 5% free cash flow yield and a quadrupled dividend since going public; and Visa with a high-margin business model converting over 50% of revenue into free cash flow while maintaining resilient payment volumes.

Investing.com•Nathan Reiff

Mar 6